DarioHealth Corp. Common Stock

Day range

$3.53 – $4.04

Open

$3.62

Prev close

$3.77

Volume

48.02K

Market cap

$36.94M

Shares out

9.8M

P/E

0.00

P/S

1.76

P/B

0.67

P/FCF

—

ROE

14913.5%

ROA

8505.6%

Debt/Equity

0.56

Div yield

0.00%

As of Oct 23, 2026

• Director departureSep 4, 2026

  On September 2, 2026, Lawrence Leisure notified the Board of Directors (the "Board") of DarioHealth Corp. (the "Company") of his decision to retire from the Board, effective September 2, 2026, for personal reasons. Mr. Leisure's decision to retire was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

• Executive officer departureAug 21, 2026

  On August 20, 2026, the Company and Mr. Nelson entered into a separation agreement (the "Separation Agreement"), pursuant to which Mr. Nelson will cease to serve as the Company's President and Chief Commercial Officer effective September 1, 2026, and his employment with the Company will terminate effective September 30, 2026 (the "Separation Date").

• Public offeringJul 22, 2026

  the Company agreed to issue and sell to the investors in a registered direct offering priced at-the-market under Nasdaq rules (the "Offering") an aggregate of 2,437,060 shares (the "Shares") of the Company's common stock, par value $0.0001 per share (the "Common Stock"), and pre-funded warrants to purchase an aggregate of 1,017,499 shares of Common Stock (the "Pre-Funded Warrants"). Each Share is being sold at an offering price of $6.80 per share, and each Pre-Funded Warrant is being sold at an offering price of $6.7999, for aggregate gross proceeds of approximately $23.5 million

• Director appointmentApr 13, 2026

  On April 10, 2026, on the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors, or the Board, of DarioHealth Corp., or the Company, the Board appointed John R. Palumbo as a member of the Board, effective immediately. Mr. Palumbo, 75, brings more than 40 years of healthcare operating experience across early-stage ventures and Fortune 100 enterprises, guiding organizations through transformative growth, including supporting two companies through IPOs and leading large-scale operational and commercial transformations.

• Underwriting agreementMar 30, 2026

  The Sales Agreement provides that the Agent will be entitled to compensation at a fixed commission rate of 3.00% of the gross proceeds from the sale of the Shares on our behalf pursuant to the Sales Agreement. The Company have agreed to reimburse the Agent for its reasonable and documented out-of-pocket costs and expenses.

Days to cover

4.4

Short interest

81.62K

Avg volume

18.52K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• DarioHealth Reports First Quarter 2026 Financial and Operating Results
  neutralBenzinga· May 13, 2026
• DarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026
  neutralBenzinga· May 4, 2026
• DarioHealth Announces Publication of Sanofi Study in JMIR Demonstrating an Estimated $5,077 Medical Cost Savings Per Dario Digital Health Platform User Per Year
  positiveBenzinga· Nov 24, 2025
• DarioHealth Reports Third Quarter 2025 Financial and Operating Results
  neutralBenzinga· Nov 13, 2025
• DarioHealth Presents New Data Demonstrating Significant Reduction in Medical Costs Among Employer Populations Using Its Digital Health Platform
  positiveBenzinga· Nov 12, 2025